RT Journal Article
SR Electronic
T1 Effects of SARS-CoV-2 P.1 introduction and the impact of COVID-19 vaccination on the epidemiological landscape of São José Do Rio Preto, Brazil
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.28.21261228
DO 10.1101/2021.07.28.21261228
A1 Cecília Artico Banho
A1 Lívia Sacchetto
A1 Guilherme Rodrigues Fernandes Campos
A1 Cíntia Bittar
A1 Fábio Sossai Possebon
A1 Leila Sabrina Ullmann
A1 Beatriz de Carvalho Marques
A1 Gislaine Ceslestino Dutra da Silva
A1 Marília Mazzi Moraes
A1 Maisa Carla Pereira Parra
A1 Andreia Francesli Negri
A1 Ana Carolina Boldrin
A1 Michela Dias Barcelos
A1 Thayza M. I. L. dos Santos
A1 Bruno H. G. A. Milhim
A1 Leonardo Cecílio da Rocha
A1 Fernanda Simões Dourado
A1 Andresa Lopes dos Santos
A1 Victoria Bernardi Ciconi
A1 Caio Patuto
A1 Alice Freitas Versiani
A1 Rafael Alves da Silva
A1 Edoardo Estevam de Oliveira Lobl
A1 Victor Miranda Hernandes
A1 Nathalia Zini
A1 Carolina Colombelli Pacca
A1 Cássia Fernanda Estofolete
A1 Helena Lage Ferreira
A1 Paula Rahal
A1 João Pessoa Araújo, Jr.
A1 Jamie A. Cohen
A1 Cliff C. Kerr
A1 Benjamin M. Althouse
A1 Nikos Vasilakis
A1 Mauricio Lacerda Nogueira
YR 2021
UL http://medrxiv.org/content/early/2021/07/31/2021.07.28.21261228.abstract
AB The emergence of the new Brazilian variant of concern, P.1 lineage (Gamma), raised concern about its impact on the epidemiological profile of COVID-19 cases due to its higher transmissibility rate and immune evasion ability. Using 272 whole-genome sequences combined with epidemiological data, we showed that P.1 introduction in São José do Rio Preto, São Paulo, Brazil, was followed by the displacement of eight circulating SARS-CoV-2 variants and a rapid increase in prevalence two months after its first detection. Our findings support that the P.1 variant is associated with an increase in mortality risk and severity of COVID-19 cases in younger aged groups, which corresponds to the unvaccinated population at the time. Moreover, our data highlight the beneficial effects of vaccination indicated by a pronounced reduction of severe cases and deaths in immunized individuals, reinforcing the need for rapid and massive vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge Rede Corona-Omica BR MCTI/FINEP affiliated to RedeVirus/MCTI (FINEP= 01.20.0029.000462/20, CNPq= 404096/2020-4, CNPq fellowship= 382032/2020-9 to C.A.B), FINEP (Grant #01180149-00), Multiuser Laboratory (LMU) at Sao Jose do Rio Preto School of Medicine (FAMERP), Brazil, for their support with the use of equipments (MiSeqTM, Illumina Inc, USA). Funding support is acknowledged from FAPESP-COVID Program (Grant #2020/04836-0 to MLN), JBS Support for COVID-19 Response Research, FAPESP fellowships (2020/07419-0 to GRFC), Fundacao Butantan (FAPESP Grant #2020/10127), Capes (Grant #0001), and partly by the Centers for Research in Emerging Infectious Diseases (CREID), The Coordinating Research on Emerging Arboviral Threats Encompassing the Neotropics (CREATE-NEO) grant 1U01AI151807 awarded to NV by the National Institutes of Health (NIH/USA). MLN, PR, JPAJ are CNPq Research Fellows. The funders had no role in the design of the study, collection, analyses, or interpretation of data, writing of the manuscript, or in the decision to publish the results.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of Faculdade de Medicina de Sao Jose do Rio Preto Institutional Review Board (protocol number: CAE# 31588920.0.0000.5415)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability All SARS-CoV-2 genomes generated and analyzed in this study are available at EpiCoV database in GISAID (https://www.gisaid.org), and their respective access number are available at Supplementary Material. https://www.gisaid.org